Fidaxomicin use and clinical outcomes for clostridium difficile-associated diarrhea

Infectious Diseases in Clinical Practice

Volumn 23, Issue 1, 2015, Pages 32-35

  Eiland, Edward H ^a   Sawyer, Adam J ^a   Massie, Nicholas L ^a  

^a HUNTSVILLE HOSPITAL   (United States)

Author keywords

Clostridium difficile infection; Clostridium difficile associated diarrhea; fidaxomicin; recurrence

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN B; FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

AGED; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; DRUG USE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PEPTOCLOSTRIDIUM DIFFICILE; PHYSICAL DISEASE BY BODY FUNCTION; POLYMERASE CHAIN REACTION; RECURRENT INFECTION; RETREATMENT; RETROSPECTIVE STUDY; REVIEW;

EID: 84920928633     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0000000000000181     Document Type: Review

References (15)

1. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. Healthcare Cost and Utilization Project (HCUP) Statistical Brief #124. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf. Accessed May 7, 2014.
2. Vardakas KZ, Polyzos KA, Patouni K, et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40(1):1-8.
3. Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis. 2012;54(4):568-574.
4. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55(suppl 2):S132-S142.
5. Goldstein EJC, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis. 2012;55(suppl 2):S143-S148.
6. Dificid (Fidaxomicin) Prescribing Information. San Diego, CA: Optimer Pharmaceuticals, Inc; 2013.
7. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422-431.
8. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-289.
9. ® (fidaxomicin) tablets in the treatment of CDAD. Caring for the Ages. 2012;Nov(suppl):1-11.
10. Bookstaver PB, James TD, Siddiqui W, et al. Fidaxomicin: a new addition to the Clostridium difficile armamentarium. Curr Med Lit Gastroenterol. 2012;31(4):95-103.
11. Ghose C. Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect. 2013;2:e62.
12. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769-1775.
13. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24): 1913-1918.
14. Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(suppl 2):S154-S161.
15. Elixhauser A, Steiner C, Gould C. Readmissions following hospitalizations with Clostridium difficile infections, 2009. Healthcare Cost and Utilization Project (HCUP) Statistical Brief #145. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb145.pdf. Accessed May 7, 2014.